[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viatris Inc (VTRS)

Viatris Inc (VTRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option

VTRS : 17.56 (-1.13%)
Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

VTRS : 17.56 (-1.13%)
3 Healthcare Stocks We Keep Off Our Radar

3 Healthcare Stocks We Keep Off Our Radar

CHE : 532.25 (-0.47%)
VTRS : 17.56 (-1.13%)
BMY : 65.31 (+0.69%)
Viatris’ Quarterly Earnings Preview: What You Need to Know

Viatris is scheduled to report its second-quarter results next month, with Wall Street expecting earnings per share to remain roughly unchanged from a year ago.

XLV : 162.55 (-0.59%)
$SPX : 7,489.72 (+0.70%)
VTRS : 17.56 (-1.13%)
3 Unpopular Stocks We’re Skeptical Of

3 Unpopular Stocks We’re Skeptical Of

AGL : 91.61 (-5.31%)
VTRS : 17.56 (-1.13%)
REYN : 24.94 (-1.27%)
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

PITTSBURGH , July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6,...

VTRS : 17.56 (-1.13%)
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated

VTRS : 17.56 (-1.13%)
How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks?

Viatris has outperformed its industry peers over the past year, and Wall Street appears optimistic about the stock.

XLV : 162.55 (-0.59%)
VTRS : 17.56 (-1.13%)
ANIP : 79.24 (-1.48%)
1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds

MGNI : 19.30 (-0.46%)
VFC : 14.32 (-4.28%)
VTRS : 17.56 (-1.13%)
How Is Zoetis’ Stock Performance Compared to Other Healthcare Stocks?

Zoetis has underperformed its industry peers over the past year, yet Wall Street remains optimistic about the stock.

XLV : 162.55 (-0.59%)
VTRS : 17.56 (-1.13%)
ZTS : 77.29 (+1.66%)

Barchart Exclusives

This Analyst Just Downgraded Apple Stock. Here's Why.
Apple stock sinks as muted guidance makes GF Securities downgrade it to 'Hold.' Here’s what the investment firm said in its research note today. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.